|Mr. Josiah C. Hornblower||Co-Founder & Chairman||420.43k||N/A||1976|
|Dr. Taylor H. Schreiber||Co-Founder, CEO & Director||526.11k||N/A||1980|
|Dr. Arundathy Nirmalini Pandite M.B.A., M.D.||Chief Medical Officer||583k||N/A||1959|
|Ms. Casi DeYoung||Chief Bus. Officer||440.66k||N/A||1971|
|Mr. Andrew R. Neill M.B.A.||Chief Financial Officer||N/A||N/A||1986|
|Conor Richardson||Sr. Director of Fin. & Investor Relations||N/A||N/A||N/A|
|Dr. Abhinav A. Shukla Ph.D.||Chief Technical Officer||N/A||N/A||N/A|
|Ms. Erin Ator Thomson J.D.||Gen. Counsel||N/A||N/A||1980|
|Dr. Thomas Lampkin Pharm.D.||Head of Regulatory Affairs||N/A||N/A||N/A|
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc.’s ISS governance QualityScore as of 1 July 2021 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.